Highlights embody: a memorandum of understanding with Memorial Sloan Kettering Most cancers Heart and a novel new partnership with Boundless Bio, a next-generation precision oncology firm
SOPHiA GENETICS’ next-generation answer CarePath, fueled by present actual world observational information, was previewed for attendees
BOSTON and GENEVA, Switzerland, Sept. 21, 2022 (GLOBE NEWSWIRE) — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software program firm within the healthcare space, hosted its first-ever Investor Day on Tuesday, September 20, 2022, in New York Metropolis.
The occasion, hosted by the CEO and Co-Founder Dr. Jurgi Camblong and members of the chief management staff, supplied a roadmap of the Firm’s long-term imaginative and prescient and highlighted new industrial alternatives and partnerships. One takeaway from the occasion was SOPHiA GENETICS’ acceleration into the Biopharma space, which opens the door for brand spanking new alternatives for market development. The viewers additionally heard how the Firm’s strategic enterprise mannequin permits for it to proceed to offer sturdy depth within the medical space.
“A key theme all through the day was how we innovate; how SOPHiA GENETICS, from its inception, has recognized alternatives within the healthcare trade for innovation and acceleration of information sharing to advance drugs, analysis and affected person care,” mentioned Jurgi Camblong, CEO and Co-Founder, SOPHiA GENETICS. “Our imaginative and prescient is made potential by the robust basis our firm has been constructed on, in addition to the strategic relationships we’ve fashioned to additional our mission of democratizing data-driven drugs.”
New Collaboration with One of many High-Ranked Most cancers Facilities in america
SOPHiA GENETICS lately introduced a memorandum of understanding to enter right into a collaboration with Memorial Sloan Kettering Most cancers Heart (“MSK”). As soon as executed, the collaboration agreements will mix today techs the ability of SOPHiA GENETICS’ massive, world community and deep experience in predictive algorithms with MSK’s medical experience in most cancers genomics. The collaboration agreements may also enable SOPHiA GENETICS’ world community of healthcare suppliers entry to MSK’s proprietary tumor sequencing exams reminiscent of MSK-IMPACT®, for analyzing tumors. Moreover, the collaboration agreements will mix MSK’s wealthy precision oncology information with the SOPHiA CarePath™ module to allow the acceleration of actionable insights from information to enhance affected person outcomes.
“Our imaginative and prescient is to broaden entry to world-class information, together with to our present community, which contributes to the collective intelligence of the SOPHiA GENETICS platform,” mentioned Philippe Menu, M.D.-Ph.D., Chief Medical Officer, SOPHiA GENETICS.
Enabling Biotech Growing Novel Most cancers Therapies Focusing on Oncogene Amplification
SOPHiA GENETICS introduced a partnership with Boundless Bio, a next-generation precision oncology firm growing progressive therapeutics directed in opposition to extrachromosomal DNA (ecDNA) in oncogene amplified cancers.
It has been properly established that sufferers with oncogene amplification usually don’t profit from customary of care most cancers remedies, and in contrast to different types of oncogenic gene alterations, oncogene amplification regularly happens on ecDNA. ecDNA are round models of nuclear DNA which are distinct from regular chromosomes and are the first web site for top copy quantity amplification in most cancers. Boundless Bio is growing the primary ecDNA-directed therapies (ecDTx) together with a precision diagnostic technique referred to as ECHO (ecDNA Harboring Oncogenes) to detect ecDNA from a affected person’s routine tumor sequencing information.
The partnership between Boundless Bio and SOPHiA GENETICS will additional develop ECHO to be used in ecDTx medical trials.
SOPHiA GENETICS’ distinctive means to harmonize information derived from various genomic devices and deploy as a strong, standardized answer allows a brand new mannequin for medical trial testing. This decentralized, world genomic answer mixed with Boundless Bio’s ecDTx drug growth capabilities goals to unlock worth by breaking the obstacles inherent to the normal central lab strategy; optimizing affected person choice and medical trial design; and enabling a worldwide collective community of main hospitals and educational facilities to successfully ship new therapy choices to sufferers with oncogene amplified cancers.
“We’re happy to associate with SOPHiA GENETICS for the event of Boundless Bio’s ecDNA detection algorithm, ECHO, right into a medical trial system,” mentioned Peter Krein, Ph.D., Vice President of Precision Medication at Boundless Bio. “The flexibility to determine sufferers with ecDNA pushed tumors is essential to our mission in addressing this space of excessive unmet medical want. SOPHiA GENETICS’ distinctive experience in growing cloud based mostly IVD NGS software program algorithms makes them a perfect associate to develop ECHO into an investigational system.”
DEEP-Lung-IV Multimodal Medical Examine Fuels New SOPHiA Carepath Platform
In late 2021, SOPHiA GENETICS launched a DEEP-Lung-IV Multimodal Medical Examine with the objective of aggregating real-world multimodal (genomic, medical, organic and radiomic) information for sufferers with metastatic non-small cell lung most cancers. The examine has garnered curiosity from top-tier facilities globally, with a powerful affected person recruitment pattern; to-date, almost 900 sufferers throughout 23 websites have been enrolled within the examine. As sufferers have been today techs adopted alongside the affected person journey, information units have been collected and analyzed by SOPHiA GENETICS’ machine studying algorithm to foretell how the sufferers will reply to immunotherapy and why.
These sturdy and rising affected person information will inform SOPHiA GENETICS’ synthetic intelligence and machine studying that may gasoline the forthcoming SOPHiA CarePath™ module, a brand new product that will likely be launched on the SOPHiA DDM™ Platform and goals to be the car healthcare practitioners can use to leverage the real-world, real-time insights obtained from this today techs examine. The SOPHiA CarePath™ module will present the next advantages:
- Visualizing information type a single affected person in a holistic method (genomic, medical, organic and radiomic)
- Enable suppliers to cohort sufferers within the context of comparable sufferers from different establishments
Alongside these bulletins, a full recording of the occasion is on the market on the Investor Relations web page of the corporate’s web site.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software program firm devoted to establishing the follow of data-driven drugs as the usual of care and for all times sciences analysis. It’s the creator of the SOPHiA DDM™ Platform, a cloud-native platform able to analyzing information and today techs producing insights from complicated multimodal information units and completely different diagnostic modalities. The SOPHiA DDM™ Platform and associated options, services are at present utilized by a broad community of hospital, laboratory, and biopharma establishments globally. For extra info, go to SOPHiAGENETICS.COM, or join on Twitter, LinkedIn, Fb, and Instagram. The place others see information, we see solutions
SOPHiA GENETICS merchandise are for Analysis Use Solely and never to be used in diagnostic procedures, except specified in any other case. The data on this press launch is about merchandise which will or might not be accessible in numerous international locations and, if relevant, might or might not have acquired approval or market clearance by a governmental regulatory physique for various indications to be used. Please contact firstname.lastname@example.org to acquire the suitable product info to your nation of residence.
SOPHiA GENETICS Ahead-Trying Statements:
This press launch comprises statements that represent forward-looking statements. All statements apart from statements of historic details contained on this press launch, together with statements concerning our future outcomes of operations and monetary place, enterprise technique, merchandise and know-how, in addition to plans and goals of administration for future operations, are forward-looking statements. Ahead-looking statements are based mostly on our administration’s beliefs and assumptions and on info at present accessible to our administration. Such statements are topic to dangers and uncertainties, and precise outcomes might differ materially from these expressed or implied within the forward-looking statements as a result of varied elements, together with these described in our filings with the U.S. Securities and Change Fee. No assurance might be on condition that such future outcomes will likely be achieved. Such forward-looking statements contained on this press launch converse solely as of the date hereof. We expressly disclaim any obligation or endeavor to replace these forward-looking statements contained on this press launch to mirror any change in our expectations or any change in occasions, situations, or circumstances on which such statements are based mostly, except required to take action by relevant regulation. No representations or warranties (expressed or implied) are made in regards to the accuracy of any such forward-looking statements.
Senior Supervisor, Media & Communications
Head of Investor Relations
today techs href=”https://www.globenewswire.com/Tracker?data=cJKqC3pKoa7movI5WaWvh81ZgMn18a73RqX4lYsCedkdgkQ2vb9DXgRhLWVmKd_9Dm5RdrHOz9kFEW85qoZJEfitDiiHVKQf8xTZAJ0cDCQ=” rel=”nofollow noopener” title=”email@example.com”>firstname.lastname@example.org